Orgenesis has signed a co-development agreement with Accelix to integrate advanced optic technologies, cartridges, and software onto POCare platform.
Cell and gene therapy company, Orgenesis, has signed a co-development agreement with Accelix, a company that provides assay migration and delivery platform for on-demand process analytics, it was announced in an Oct. 16, 2019 press release.
Under the terms of the agreement, Orgenesis will be afforded the opportunity of integrating Accellix’s proprietary optic system, cartridges, reagents, and software into its Point of Care (POCare) cellular therapy processing services and platform. By amalgamating these systems and services, it is hoped that further advancement of Orgenesis’ quality control systems will be achieved.
“By partnering with Accellix and integrating its advanced optic technologies, cartridges, and software, we believe that this will advance Orgenesis’ processing capabilities for different types of cells for our POCare services and platform,” said Vered Caplan, CEO of Orgenesis, in the press release. “We believe the Orgenesis POCare platform can deliver a transformative option to the cell and gene therapy market that will lower costs in order to potentially bring our autologous therapies to patients in a cost effective, high quality, and scalable manner.”
Financial details of the agreement were not disclosed.
Source: Orgenesis
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.